OUR HISTORY
OUR HISTORY
SLC’s drug discovery and development division was established in 2012 focusing on developing novel small molecule kinase inhibitors for the treatment of human diseases with unmet medical needs. Our experiences and expertise in the kinase biology and drug discovery and development allow us to deliver novel therapies against new and untapped kinase targets with a greater likelihood of success and better outcomes for patients. This powerful target discovery engine has generated a robust drug candidate pipeline of novel kinase inhibitors for the treatment different type of cancers.
In addition, the bioreagent products can also be used to develop diagnostic kits (Biomarkers) to support discovery and development of drug candidates using a personalized medicine approach. This entails identifying those patients with the related kinase defect and applying a specific targeted therapy against the defective kinase which will improve SLC’s prospects of successful clinical development and improved patient outcome.
SignalChem Diagtech Corp. and SignalChem Plantech Corp., businesses were established in 2018 and 2019 to capture rapid growth opportunities and fully utilize SignalChem’s deep knowledge and expertise in protein engineering. SignalChem Diagtech Corp. focus on the development, manufacturing, sales and technical services of IVD products. SignalChem Plantech Corp. focus on the biosynthesis of recombinant proteins and secondary metabolites in green plants.